We present the first analytical approach to demonstrate the in situ imaging of metabolites from formalin-fixed paraffin-embedded (FFPE) human tissue samples. Using high-resolution Matrix-Assisted Laser Desorption/Ionization Fourier-Transform Ion Cyclotron Resonance Mass Spectrometry Imaging (MALDI-FT-ICR MSI), we conducted a proof of principle experiment comparing metabolite measurements from FFPE and fresh frozen tissue sections, and found an overlap of 72% amongst 1700 m/z species. In particular, we observed conservation of biomedically relevant information at the metabolite level in FFPE tissues. In biomedical applications, we analysed tissues from 350 different cancer patients, and were able to discriminate between normal and tumour tissues, and different tumours from the same organ, and found an independent prognostic factor for patient survival. This study demonstrates the ability to measure metabolites in FFPE tissues using MALDI-FT-ICR MSI, which can then be assigned to histology and clinical parameters. Our approach is a major technical, histochemical and clinicopathological advance that highlights the potential for investigating diseases in archived FFPE tissues.
INTRODUCTION
A broad spectrum of diseases are diagnosed based on histology -the microscopic anatomy of samples resected from patients. The gold standards for histopathological analysis, valid diagnosis and patient treatment are based on formalin-fixed paraffin-embedded (FFPE) patient samples. Formalin fixation was first reported in 1893 and has been shown to maintain tissue integrity for many years [1] . Formalin fixation preserves tissues by forming methylene bridge cross-linkages between proteins, and the sample is then dehydrated with graded ethanol, immersed in an organic solvent (e.g. xylene) to clear the alcohol, and then infiltrated with molten paraffin. Much effort has been spent in the last decades on standardizing FFPE protocols. Compared to fresh frozen (FF) samples, FFPE tissues can be easily archived for many years with corresponding patient data for retrospective reassessment and clinicopathological studies. While histology is a reliable tool, advanced techniques have expanded knowledge of the molecular and genetic content of tissues, which is not readily apparent when assessing patient samples based on histology [2, 3] .
Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry Imaging (MALDI-MSI) is a
powerful technique combining mass spectrometry with histology, allowing for the spatiallyresolved and label-free detection of hundreds to thousands of compounds within a single tissue section. Depending on the sample preparation and instrumentation, MALDI-MSI can detect a wide variety of molecular classes, e.g. proteins, peptides, lipids, drugs and others [4, 5] . Recently, the development of devices that have a high resolving power for small molecular weight compounds, e.g. AP-SMALDI-Orbitrap or MALDI-FT-ICR MS, have allowed for the in situ detection and visualization of metabolites and different metabolic states within tissues [6, 7] . FF samples are currently preferred over FFPE in tissue-based MALDI-MSI studies. This is primarily due to concerns regarding the effect of chemical processing on molecular content, molecular delocalization from washing steps and the belief that paraffin would cause ion suppression [4, 8] . At present, MALDI-MSI of FFPE tissue has primarily concentrated on protein and peptide content, the protocol for which utilizes deparaffination, antigen-retrieval and enzyme digestion adapted from immunohistochemical procedures [4] .
Measurements of small molecule metabolites (<1500 Da) are emerging in importance as these levels reflect gene expression, protein function, environmental factors and metabolic pathways [9] . In addition, perturbed metabolism is a hallmark of many diseases, e.g. cancer and degenerative conditions [10] . While metabolite measurements from homogenized FFPE tissue using liquid based mass spectrometry have been conducted [11, 12] , liquid samples cannot provide information on molecular spatial distribution. This is particularly important as tissues are highly complex and heterogeneous systems. Given the ability to measure metabolites from FFPE samples using liquid mass spectrometry, we hypothesized that it should also be feasible in MSI.
We present the first study of in situ MALDI-FT-ICR MSI of metabolites from FFPE tissue samples. Using a simple experimental workflow and different comparison paradigms, we demonstrate the localization of different metabolites, which was used to answer tumour biology and clinical questions.
MATERIALS AND METHODS

Collection of tissue samples
Primary surgical resection specimens were obtained from patients diagnosed with colon adenocarcinoma (n = 102; all pT2 according to UICC classification [13] ), breast cancer (n = 33), gastric adenocarcinoma (n = 102), renal oncocytoma (n = 21), chromophobe renal cell carcinoma (n = 11), and oesophageal adenocarcinoma (n = 53). Samples were collected between 1993 and 2010 at the Dept. of Surgery, Klinikum Rechts der Isar, Munich, Germany, and at Leiden University Medical Center, Leiden, the Netherlands. This study was approved by the local Ethics Committees; all patients provided informed, signed consent (Germany);
Code of conduct for responsible use of human tissue for research (the Netherlands). Followup data were available for patients and survival rates calculated from the date of surgical resection to the date of last follow-up or death. All FFPE samples were collected in Munich. Table S1 is a summary of patient numbers and sample type (FF or FFPE).
FFPE samples were fixed for 12-24 hours in 10% Neutral Buffered Formalin then embedded in paraffin using standardised and automated procedures. The samples were dehydrated in graded ethanol, cleared with xylene, and embedded in molten paraffin [14] . Fresh-frozen samples were stored post-surgery in liquid nitrogen until measurement. Frozen (12µm) and FFPE sections (4µm) were mounted onto indium-tin-oxide (ITO) coated glass slides (Bruker Daltonik, Bremen, Germany) pre-treated with 1:1 poly-L-lysine (Sigma Aldrich, Munich, Germany), and 0.1% Nonidet P-40 (Sigma).
MALDI imaging mass spectrometry
Prior to matrix application, FF sections were dehydrated in a vacuum for 1h at room temperature, FFPE sections were incubated for 1 hr at 70°C, de-paraffinized in xylene (2x 8 minutes), and allowed to air-dry. Matrix application and MALDI-MSI were conducted as previously described. [7] Briefly, frozen and FFPE samples were coated in 10mg/ml 9-aminoacridine matrix in 70% methanol using a SunCollect sprayer (Sunchrom, Friedrichsdorf, Germany) [7] . MSI was performed in negative ion mode on a Bruker Solarix 7T FT-ICR MS (Bruker), over a mass range of m/z 50 -1000, and 60µm lateral resolution.
All measurements included a non-tissue measurement region as a background control.
Following measurement, the matrix was removed with 70% ethanol, stained with HE, coverslipped, scanned with a Mirax Desk scanner (Zeiss, Göttingen, Germany) with a 20x magnification objective, and co-registered to respective MSI data using FlexImaging v. 4.0 (Bruker). Stained slides were examined by a pathologist and samples excluded if they contained no tumour or if the section was lost during HE staining. Using FlexImaging, acquired data were normalised against the root mean square of all data points, and histologyguided regions of interest (ROIs) were annotated (e.g. tumour or mucosa) and the spectral data exported [7] . On-tissue MS/MS was conducted on FFPE tissue samples using continuous accumulation of selected ions mode and collision induced dissociation (CID) in collision cell [7] . To test the reproducibility we measured consecutive serial sections of breast cancer tissue microarrays (TMAs, n = 3; tissue cores = 40) on separate days.
Bioinformatics and Statistical Analysis
Subsequent data processing was performed with a MATLAB script using the bioinformatics and image processing toolboxes (v.7.10.0, MathWorks, Natick, MA, USA). All exported spectra underwent baseline subtraction to remove noise, resampling to lower data dimensionality, and smoothing to remove tissue and measurement artifacts [15] . Peak picking was conducted using a modified version of the LIMPIC algorithm [16] , using m/z 0.0005 minimal peak width, signal to noise threshold of 2, and intensity threshold of 0.01%. Peaks were picked if found in 80% of the samples in each group (e.g. tumour or mucosa). Isotopes were automatically identified and excluded. To identify statistically significant differences in m/z values, the peaklists were analysed with the Mann-Whitney U test and BenjaminiHochberg post hoc test (alpha = 0.05). If not otherwise stated, m/z values that were found also to occur in the non-tissue measurement region (acting as a background control) were excluded from these peak lists on the basis that m/z values that occurred in the non-tissue region could also be molecules from the slide surface.
PCA and heatmaps were created with MetaboAnalyst 3.0 (http://www.metaboanalyst.ca) [17] . Peak lists with respective intensities for ROIs were uploaded to MetaboAnalyst, processed with a mass tolerance of m/z 0.0001, no data filtering, and log transformed. The resultant PCA and heatmaps of metabolite data were exported as figures.
Significance Analysis of Microarrays (SAM) was used to identify disease-free survivalassociated m/z values (q -value < 0.05). The average peak intensity was used to split patients into good and poor survivor groups and significant differences in their survival were determined with the log-rank test. Multivariate survival analysis was performed using Cox proportional hazards regression models. All calculations were performed within R ('samr' and 'survival' packages). P-values <0.05 were considered significant.
Metabolite Identification
Metabolites were identified either by comparison to observed MS/MS spectra with standard compounds or by matching accurate mass with Metlin (http://metlin.scripps.edu/index.php) and the Human Metabolome Database (http://www.hmdb.ca) [18, 19] . Search parameters were 3 ppm mass tolerance and [M-H] -charge. In silico analysis using Bruker DataAnalysis and SmartFormula was used to determine the molecular formula of m/z 256.9975. Raw spectra from the Barrett's TMA where m/z 256.9975 was highly intense were extracted and examined in Bruker DataAnalysis. The spectra were recalibrated using 9-AA as a reference peak ([M-H]-193.07712), and then analysed using a FTMS peak finder. Using
SmartFormula, H/C ratio was set from 0 to 3; the number of rings and double bonds were restricted to 0.5 to 40; and the option to automatically detect isotopic mass was activated.
Molecular formulas were predicted allowing structures containing sulphate and phosphate;
and M-H, M+H2O-H, M+Na-H2, M+K-H2 as negative adducts. Mass error tolerance was set at < 1 ppm; mass charge as -1. mSigma values -the match factors between the measured isotopic pattern and theoretical pattern of a given formula -less than 50 were considered a good match. A database search using Compound Crawler, including ChEBI, Chemspider, KEGG, and Metlin, was performed to produce compound structures.
RESULTS
In a first proof of principle study, we examined whether it was possible to conduct metabolite measurements from FFPE samples and if the detected compounds were comparable to those found in FF tissues. As stated, MALDI-MSI for FFPE protein and peptide content require many preparation steps [1] . In contrast, our workflow for FFPE metabolite imaging consisted only of deparaffination and matrix application ( Figure 1 ). 
Comparison of FF and FFPE
Reproducibility assessment
To examine reproducibility of our FFPE metabolite imaging approach, serial sections of Figure S3 ). This is a particular breakthrough as it has been thought that FFPE tissue processing would cause delocalization of molecules leading to inaccurate distributions [8] .
Sample ion maps of other m/z values that occur in both FF and FFPE tissue are presented in Figure S4 . It can be seen that most metabolites occur with similar intensities and localizations in both FF and FFPE. Interestingly, despite the embedding process, we could annotate some 
Identification and validation of metabolites
On-tissue MS/MS was conducted on FFPE sections to confirm that the detected peaks corresponded to metabolites. Focusing on nucleotides and metabolites from the central carbon metabolism pathway, AMP, GMP, and GDP were confirmed by comparison of ontissue MS/MS spectra to standard compounds ( Figure S5 ). Hexose-6-phosphate, glycerol monophosphate and UDP were confirmed by accurate mass matching to databases.
Distinction between tumour and normal tissue specimens
To test whether metabolite profiles could distinguish between normal and diseased tissue, a TMA (n = 28 patient tissue samples) with matched normal and colon cancer tissue was measured and stained afterwards with haematoxylin and eosin (HE). Regions of interest (ROIs) for normal mucosa and tumour were annotated using histology as a guide. 
Distinction between chromophobe renal cell carcinoma and renal oncocytoma
Chromophobe renal cell carcinoma (ChRCC) and renal oncocytoma have different clinical outcomes. The separation of these tumour types using light microscopy of conventional HE staining remains difficult in some cases. Therefore our metabolite imaging approach was applied to discriminate between these tumour types that arise from renal tissue. 
MALDI-FT-ICR MSI was conducted on
Survival analysis reveals an independent prognostic marker in oesophageal adenocarcinomas
We next investigated whether metabolite imaging could be used to address patient survival outcome. Tumour-specific spectral data was obtained from a TMA containing 53 oesophageal adenocarcinomas and survival analysis was conducted ( Figure S9 ). The mean age at the time of surgery was 61 years, and the maximum follow up time was 162 months.
Median disease-free survival time was 15 months, and median overall survival time was 18 months. The clinicopathological parameters of the tumour set are summarized in Table S2 .
Uni-and multivariate statistical analysis (with correction of cumulative alpha-errors) found m/z 256.9975 correlated significantly with disease-free survival, and constitutes an independent prognostic parameter in multivariate analysis, in comparison to the clinical standard for tumour staging, the TNM system according to UICC classification ( Figure 6 ) [13] . As no database annotation was available for m/z 256.9975, in silico molecular formula analysis utilising isotope fine structure was used to provide an identity. Analysis of the isotopic pattern predicts that m/z 256.9975 has a molecular formula C 6 H 10 O 9 S (mSigma 28.6). An integrated structure search found eight different compounds with the molecular formula C 6 H 10 O 9 S (Figure S10 ), which were deoxy sugar acids with sulphate esters.
DISCUSSION
This is the first study describing metabolite measurements with MALDI-FT-ICR MSI using (Figure 3 ), confirming the energy competition also known as Warburg effect -the increased rate of glycolysis in tumours [10] . In FFPE samples, peaks of metabolites were detected in low mass range (m/z 50 -400) having similar intensity compared to FF. In contrast, peak intensities were significantly reduced above the mass range of m/z 600. This result corresponds with the expectation that tissue embedding process and the removal of paraffin wax by solvents (e.g. xylene) remove lipids, too. Despite this, we found a conservation of solvent-resistant lipids which remain present in formalin-fixed tissue ( Figure S4 ). It is known that cellular components such as nucleic acids, carbohydrates, and lipids are not fixed directly by formaldehyde, but can be trapped in the network of cross-links between proteins [21] . In a previous study, it was suggested that methylene chains of free, unbound tissue lipids are removed from the tissue, while solvent-resistant lipids remain present in formalin-fixed tissue due to being locked into protein-lipid complex matrices, predominantly in the membranes [22] .
Currently, the outcome of metabolic research based on FFPE tissue is very restricted although analysis of FFPE samples in a clinical and biological context is desirable. Commonly used techniques in metabolomics are nuclear magnetic resonance spectroscopy and liquid based MS (e.g. liquid chromatography MS and gas chromatography MS). Efforts were made to establish extraction and purification protocols for metabolite detection by liquid based MS [11, 12] . But these protocols face challenges as liquid based MS techniques require large tissue amounts in order to achieve satisfactory metabolite yields for analyses. Additionally, tissue homogenizing leads to loss of specificity reducing significant results. An advantage of MSI is that spatial and chemical integrity are maintained and therefore enables detailed readouts from images by performing virtual micro-dissection (defined as region of interest) of spatially-resolved mass spectra. In a proof of principle this information was used to successful discriminate the metabolite content of normal and diseased tissue (Figure 4 ).
Moreover, we determined the metabolic 'fingerprints' of chromophobe renal cell carcinoma adenocarcinomas by MSI to clinical data revealed an independent prognostic factor for overall survival ( Figure 6 ). In silico analysis of the prognostic m/z value indicates that this molecule is most likely a deoxy sugar acid with ester sulphate. Previous studies have shown that duodenal and gastric mucus contains acid polysaccharides with ester sulphate [24, 25] . It has been reported that sulphated polysaccharides are associated with Barrett's oesophagus and Barrett's carcinoma [26] . Given the functions of sulphated polysaccharide structures as ligands, alterations in the sulphation of metaplastic cells, as present in Barrett's oesophagus, could have important effects on differentiation and malignant progression [27] .
MALDI-MSI of FFPE tissue has so far concentrated only on protein and peptide analyses.
Protocols for peptide measurements from TMAs are more complex and incorporate an antigen retrieval step, deparaffinization, in situ trypsin digestion and matrix application which can challenge the reproducibility. In this study we acquired reliable and reproducible data from TMAs and detected much more m/z species compared to the achieved number of molecules obtained in peptide measurements on FFPE tissues [28] .
The ability to image metabolites is the starting point to investigating metabolic pathways in FFPE tissues, and should enable distinguishing the exact location of metabolic disturbances.
In addition, the continual improvement in the mass resolution of MSI instrumentation may increase the likelihood of detecting low abundance metabolites that may be masked by the peaks of more abundant molecules. This would in turn lead to improved annotation of detected peaks. Prospectively, it is likely possible to measure hundreds of molecules and generate pathways from thousands of patients when using TMAs. Given that FFPE samples have been archived for decades in hospitals and universities around the world, this presents an unparalleled source of information on diseases. In summary, our study is therefore not only a major technical advance but may have direct impact on predicting patient outcome and diagnosis, and tissue-based research in general. This article is protected by copyright. All rights reserved 
